Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a … will highlight its proprietary Axiomer™ ADAR-mediated RNAediting platform, along with updates on its pipeline of …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … review of the Company’s clinical-stage programs and RNAediting technology platforms. A webcast replay of the …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board. Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the Company’s …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … Annual Conference A presentation titled “Therapeutic RNAediting by Axiomer ® editing oligonucleotides” by Janne …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced that it has …
… two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets … collaboration are not disclosed. ProQR is developing its RNA platform technology in areas of ophthalmology, cystic … look forward to collaborating with ProQR and its exciting RNAediting technologies.” About ProQR ProQR Therapeutics is …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced the pricing …